News
Lymphoma patients to benefit from new CAR T Cell Therapy option now available in Australia
5 August 2021
Kite, a Gilead company, today announced that its Chimeric Antigen Receptor (CAR) T cell therapy, Yescarta® (axicabtagene ciloleucel), is now publicly funded and available to patients in Australia.
Yescarta is now publicly funded for patients with four types of aggressive non-Hodgkin lymphoma.
Australian lymphoma patients will now have access to a new frontline therapy for CLL
30 November 2020
The combination of VENCLEXTA plus obinutuzumab will be available as a fixed duration therapy for previously untreated patients with CLL who are unfit for chemotherapy.
The Federal Minister for Health, The Hon. Greg Hunt MP, has announced that Venclexta® (venetoclax) in combination with obinutuzumab will be available to eligible Australians with Chronic Lymphocytic Leukaemia (CLL) as a first line therapy via the Pharmaceutical Benefits Scheme (PBS) from the 1st December 2020.
New hope for Australian leukaemia and lymphoma patients with key treatment option listed on PBS
30 August 2020
A key new cancer treatment has just become more accessible for Australians fighting specific forms of leukaemia and lymphoma, thanks to the Morrison Government’s listing of Calquence® on the Pharmaceutical Benefits Scheme (PBS).
On September 1, Calquence® (acalabrutinib) will be listed on the PBS for the first time for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma.
CAR T-cell Therapy for Aggressive B-cell Lymphoma
28 January 2020
The Federal Health Minister, Hon. Greg Hunt MP announced today at Peter MacCallum Cancer Centre, that CAR T-cell therapy (Kymriah, from Novartis) will be manufactured and reimbursed in Australia for eligible adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (FL) and primary mediastinal B-cell lymphoma (PMBCL).